Drug shortage
Cisatracurium Besylate Injection · Teva Pharmaceuticals USA, Inc.
FDA drug shortage · To Be Discontinued · updated Jan 6, 2025
Key facts
| Generic name | Cisatracurium Besylate Injection |
|---|---|
| Proprietary name | Cisatracurium Besylate Preservative Free |
| Company | Teva Pharmaceuticals USA, Inc. |
| Presentation | CISATRACURIUM BESYLATE PRESERVATIVE FREE, Injection, 200 mg/20 mL (NDC 0703-2045-03) |
| Dosage form | Injection |
| Strength | 200 mg/20 mL |
| Status | To Be Discontinued |
| Therapeutic category | Anesthesia |
| Package NDCs | 0703-2045-03 |
| First posted | Jan 6, 2025 |
| Last updated | Jan 6, 2025 |
| Discontinued | Jan 6, 2025 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: